drugset / Trial / NCT03093922
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Phase 2
Active not recruiting
32 enrolled
Memorial Sloan Kettering Cancer Center
Genentech, Inc. · collabOhio State University · collabTargos · collabUniversity of Chicago · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.
Timeline
- Start
- 2017-03-22
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |